Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marat Goldenberg

Vascular Surgery Augusta, GA Medical Doctor

NPI 1336190552 CMS profile 332492

1350 Walton Way, Augusta, GA 30901

Open in the dashboard

General payments

$15,911

310 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marat Goldenberg of Augusta, GA is reported in the CMS Open Payments database as having received $15,911 across 310 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,832 54
2024 General $1,535 44
2023 General $3,004 41
2022 General $3,764 53
2021 General $1,938 51
2020 General $1,014 23
2019 General $1,824 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marat Goldenberg
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Marat Goldenberg were reported at $2,832. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Marat Goldenberg Vascular Surgery median Middle half National median
2019 $1,824 $796 $226–$2,363 $163
2020 $1,014 $348 $118–$1,110 $114
2021 $1,938 $471 $158–$1,421 $132
2022 $3,764 $725 $222–$2,183 $149
2023 $3,004 $836 $257–$2,440 $160
2024 $1,535 $909 $252–$2,619 $164
2025 $2,832 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Penumbra, Inc. $2,750 38 payments
  2. Cardiovascular Systems Inc. $2,080 46 payments
  3. Silk Road Medical, Inc. $1,762 12 payments
  4. Inari Medical, Inc. $1,670 34 payments
  5. Endologix, Inc. $1,308 10 payments
  6. Bard Peripheral Vascular, Inc. $1,232 38 payments
  7. Shockwave Medical, Inc $503 10 payments
  8. PolyNovo North America LLC $463 8 payments
  9. Abbott Laboratories $383 5 payments
  10. W. L. Gore & Associates, Inc. $336 6 payments
  11. Other $3,425 103 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,002 300 payments
  2. Travel and Lodging $2,909 10 payments
Products named General payments · program years 2019–2025
  1. Indigo System $2,581 33 payments
  2. FLOWTRIEVER CATHETER, S $1,984 42 payments
  3. ENROUTE Transcarotid Stent $1,721 10 payments
  4. ENROUTE Transcarotid Neuroprotection System $1,721 10 payments
  5. Diamondback Peripheral $1,197 25 payments
  6. CT THROMBECTOMY SYSTEM KIT $873 26 payments
  7. Peripheral Orbital Atherectomy System $746 19 payments
  8. AFX2 Bifurcated Endograft System $550 6 payments
  9. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $472 8 payments
  10. Rotarex $354 11 payments
  11. Other $7,598 187 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

355

Median for Vascular Surgery: 122

Drug cost

$34,057

Median for Vascular Surgery: $14,135

Branded share of claims

86.5%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 42 $31,703
Clopidogrel Clopidogrel Bisulfate Brand 166 $1,103
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 99 $805
Cilostazol Generic 13 $312
Rosuvastatin Calcium Generic 20 $81
Pantoprazole Sodium Generic 15 $54

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 117 billing codes

Paid by Medicare

$136,015

Medicare's payments for the services billed

Medicare patients

1,067

Average age 75

Services billed

1,920

555 women, 512 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Ischemic heart disease 52%
Diabetes 50%
Chronic kidney disease 49%
Heart failure 39%
Atrial fibrillation 33%
Depression 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

310 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record